Use of Endocrine Therapy for Breast Cancer Risk Reduction

Publication Date: September 3, 2019

Introduction

Introduction

This guideline is relevant to women without a personal history of breast cancer (BC) who are at increased risk of developing the disease.

Diagnosis

...gnosis...

...able 1. Breast Cancer Risk Assessment ToolsHav...


Treatment

...atment...

...mary of All Recommendations...

Tamoxifen

...iscussed as an option to reduce the risk of invas...

...mmended for use in women with a history of deep ve...

...commended for women who are pregnan...

...recommended in combination with hormon...

...up should include a timely work-up of abnormal...

...with patients and health care providers sho...

...20 mg/d orally for 5 years. (EB, S)7251...

...idence-based on 5 RCTs with low risk of bias)...

...oxifene...

...e discussed as an option to reduce the risk of i...

...onger than 5 years in women with osteoporosis, in...

...ould NOT be used for BC risk reducti...

...ed for use in women with a history of deep v...

Discussions with patients and health care prov...

...GE: 60 mg/d orally for 5 years. (EB, S)7251...

...-based on 4 RCTs with low risk of bias)...

...emestane...

...uld be discussed as an alternative to tamo...

...d NOT be used for BC risk reduction in pre...

...h patients and health care providers shoul...

...mg/d orally for 5 years. (EB, M)7251

...e evidence-based on 1 RCT with low...

...strozole...

...astrozole (1 mg/day orally for 5 year...

...likely to benefit are those with one of more of...

...ians should NOT prescribe anastrozole, exemestan...

...ions between patients and health care...

...itiating an aromatase inhibitor, clinici...

...ians should inform women also of the po...

...weigh harms; Evidence quality: high; Strong-based...


...3. Summary of Agent IndicationsHaving tro...


...Effects of Endocrine TherapyHaving...